Figure 4From: A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosisCMTC and prediction in pCR of neoadjuvant chemotherapy. (A) The percentage of pCR between non-Her2+/TN tumors (non-H+/TN) and Her2+/TN tumors (H+/TN) and within the three CMTC groups of the 248 breast cancers with neoadjuvant chemotherapy. (B) Comparison of area under the curve (AUC) to predict pCR in CMTC-3 tumors (CMTC-3 vs CMTC-1 and CMTC-2; P = 0.0001), Her2+/TN tumors (Her2+/TN vs non-Her2+/TN; P = 0.0001), Her2+ tumors (Her2+ vs Her2-; P = 0.0245) and TN tumors (TN vs non-TN; P = 0.0052). By comparing the gene profiles of individual tumors with CMTC-3, a correlation coefficient (r) was calculated as an index reflecting its degree of similarity to the expression pattern of CMTC-3 tumors. The two graphs show the relationship between r value and pCR (C) in the 111 Her2+/TN cancers and (D) in all 248 cancers. pCR status (deep pink), Her2+ status (deep pink) and TN status (dark blue), respectively, are indicated by the bottom bars. AUC = area under the curve; CMTC = ClinicoMolecular Triad Classification; Her2 = human epidermal growth factor receptor 2; pCR = pathological response; TN = triple-negative.Back to article page